drugset / Trial / NCT04859452
A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a four-part, single-center, open-label, single-sequence crossover phase I clinical study to characterize the Drug-Drug Interaction (DDI) potential of DBPR108 at steady-state with Metformin hydrochloride, Glibenclamide, Valsartan, or Simvastatin in Healthy Subjects. This study also aims to evaluate the safety and tolerability of DBPR108 in the presence of Metformin hydrochloride, Glibenclamide, Valsartan, or Simvastatin.
Timeline
- Start
- 2021-05-26
- Primary completion
- 2021-07-03
- Completion
- 2021-07-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DBPR108 | Small molecule | 100 mg | Oral |
| Subject | Glyburide | Small molecule | — | Oral |
| Subject | Metformin | Small molecule | — | Oral |
| Subject | Simvastatin | Small molecule | — | Oral |
| Subject | Valsartan | Small molecule | — | Oral |
Indications
No indication recorded.